ADVERTISEMENT
Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer
Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast cancer who previously underwent endocrine therapy.
Source:
Curigliano G. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA1000
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement